Beta Finch - Healthcare & Devices - EN Podcast By Beta Finch cover art

Beta Finch - Healthcare & Devices - EN

Beta Finch - Healthcare & Devices - EN

By: Beta Finch
Listen for free

Health insurers, medical device makers, and life sciences companies. AI-powered earnings call analysis for Healthcare & Devices (HEALTHCARE). Two AI hosts break down quarterly results, key metrics, and market implications in digestible podcast episodes.2026 Beta Finch
Episodes
  • UnitedHealth Q4 2025 Earnings Analysis

    UnitedHealth Q4 2025 Earnings Analysis
    Mar 21 2026
    # Beta Finch Podcast Script: UnitedHealth Q4 2025 Earnings

    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown where we turn corporate speak into plain talk. I'm Alex.

    **JORDAN:** And I'm Jordan. Today we're diving into UnitedHealth's Q4 2025 results, and wow - there's a lot to unpack here.

    **ALEX:** Before we get started, I need to mention that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Right, and speaking of unpacking - UnitedHealth just delivered what I'd call a "everything but the kitchen sink" quarter. They beat expectations slightly with adjusted EPS of $16.35, but there's this massive $1.6 billion charge lurking underneath.

    **ALEX:** Yeah, that charge is wild. It's like getting three different bills at once - $800 million related to that cyberattack cleanup, a $440 million gain from selling off assets, and then a whopping $2.5 billion restructuring charge. It's clear they're doing some serious spring cleaning.

    **JORDAN:** What caught my attention is how transparent CEO Stephen Hemsley was about this being a "new age" for the company. They're essentially admitting they need to get back to basics while investing heavily in AI - we're talking $1.5 billion in 2026 alone.

    **ALEX:** Let's talk numbers first. Revenue hit nearly $448 billion, up 12% year-over-year, which is solid. But the real story is in the 2026 guidance - they're projecting adjusted EPS of greater than $17.75, which represents at least 8.6% growth.

    **JORDAN:** That guidance is interesting because it's what I'd call "cautiously optimistic." They're expecting double-digit improvements at UnitedHealthcare but only low-to-high single-digit growth across the Optum segments. It tells me they're being realistic about their turnaround timeline.

    **ALEX:** The Medicare Advantage story is probably the biggest concern for investors. Tim Noel basically said they're planning to lose 1.3 to 1.4 million Medicare Advantage members in 2026. That's not a typo - they're intentionally shrinking to focus on profitability over growth.

    **JORDAN:** And then yesterday's rate notice for 2027 was apparently even worse than expected. Noel called it "disappointing" and warned of "meaningful benefit reductions" for seniors. When a healthcare executive is that blunt about government rates, you know it's bad.

    **ALEX:** What's their strategy to deal with this? It sounds like they're doubling down on margin recovery. They expect Medicare margins to improve by about 50 basis points in 2026, but they're essentially trading membership for profitability.

    **JORDAN:** The Optum turnaround is where things get really interesting. Patrick Conway, the new Optum CEO, outlined some pretty dramatic changes. They've narrowed their provider network by 20%, streamlined risk membership by 15%, and consolidated down from 18 different electronic medical record systems to just three.

    **ALEX:** That EMR consolidation alone shows you how scattered they were. Imagine trying to implement AI tools across 18 different systems - it's like trying to conduct an orchestra where every musician is reading different sheet music.

    **JORDAN:** Speaking of AI, they claim 80% of member calls now use AI tools, and they're expecting nearly $1 billion in AI-enabled cost reductions in 2026. That's not just efficiency gains - that's transformational if they can pull it off.

    **ALEX:** Now let's talk about what came up in the Q&A, because that's where executives sometimes reveal what they're really thinking. One analyst asked about the bottom of the Medicare Advantage cycle, and you could sense the frustration in management's response.

    **JORDAN:** Right, they're clearly not happy with the regulatory environment. Hemsley mentioned $130 billion in funding reductions over the past three y

    This episode includes AI-generated content.
    Show more Show less
    8 mins
  • Thermo Fisher Scientific Q4 2025 Earnings Analysis

    Thermo Fisher Scientific Q4 2025 Earnings Analysis
    Mar 21 2026
    **BETA FINCH PODCAST SCRIPT**

    ---

    **ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown. I'm Alex, and I'm here with my co-host Jordan to dive into Thermo Fisher Scientific's Q4 2025 results. Before we get started, I want to remind everyone that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN:** Thanks Alex. And what a quarter to analyze! Thermo Fisher just delivered some really solid numbers to cap off 2025, plus they dropped a massive $9 billion acquisition announcement. There's a lot to unpack here.

    **ALEX:** Absolutely. Let's start with the headline numbers, Jordan. Q4 revenue came in at $12.21 billion, up 7% year-over-year. For the full year, they hit $44.56 billion in revenue, growing 4%. But here's what I found interesting - their adjusted EPS grew 8% in the quarter to $6.57, and 5% for the full year to $22.87.

    **JORDAN:** That EPS growth is noteworthy because it shows they're managing their operations really well despite some headwinds. CEO Marc Casper mentioned they faced over 100 basis points of margin pressure from tariffs and foreign exchange impacts. Yet they still delivered solid earnings growth - that's the power of their PPI business system at work.

    **ALEX:** Speaking of headwinds, let's talk about how different end markets performed. Pharma and biotech was the standout - high single-digit growth in Q4 and mid-single digits for the full year. That's their core market, so seeing strength there is crucial.

    **JORDAN:** Right, and Casper gave some really interesting color on customer sentiment in pharma during the Q&A. He talked about meeting with pharma CEOs who were much more optimistic, saying the tone in January customer meetings was "quite positive." He even shared this great anecdote about a pharma CEO who was so engaged in their discussion that he literally went and found his head of development mid-conversation to dive deeper into specifics.

    **ALEX:** That's the kind of customer relationship that's hard to quantify but incredibly valuable. It speaks to their "trusted partner" positioning. But not all end markets were as rosy - academic and government declined low single digits both for the quarter and full year, largely due to macro conditions in the US and China.

    **JORDAN:** Yeah, and that's reflected in their 2026 guidance assumptions. They're basically planning for similar market conditions to 2025, which seems prudent. They're guiding for 3-4% organic growth and 4-6% reported revenue growth, targeting $46.3 to $47.2 billion in revenue.

    **ALEX:** The earnings guidance is where things get interesting though. They're projecting 6-8% adjusted EPS growth, hitting $24.22 to $24.80 per share. That's pretty strong earnings leverage even with modest revenue growth.

    **JORDAN:** Exactly, and that doesn't even include the potential impact from their big acquisition announcement - Clario. This is a $9 billion deal for a digital endpoint data provider that generated about $1.5 billion in 2025 revenue. If it closes by year-end as expected, it could add another $0.45 in adjusted EPS.

    **ALEX:** Let's dig into that Clario deal because it's fascinating strategically. They're essentially buying capabilities in one of the fastest-growing areas of clinical research - digital endpoints for clinical trials. This fits perfectly with their "Accelerated Drug Development" solution that combines their pharma services and clinical research businesses.

    **JORDAN:** And Casper was really enthusiastic about this during the call. He talked about how it will enable "even deeper clinical insights" and "further accelerate the digital transformation of clinical research." Plus, they mentioned it has an attractive double-digit return profile and will be accretive to both organic growth and margins.

    **AL

    This episode includes AI-generated content.
    Show more Show less
    9 mins
  • Stryker Q4 2025 Earnings Analysis

    Stryker Q4 2025 Earnings Analysis
    Mar 21 2026
    **ALEX**: Welcome to Beta Finch, your AI-powered earnings breakdown where we cut through the noise to bring you the insights that matter. I'm Alex.

    **JORDAN**: And I'm Jordan. Today we're diving into Stryker's Q4 2025 earnings - and folks, this medical device giant just delivered what CEO Kevin Lobo called "outstanding results" across all key metrics.

    **ALEX**: Before we jump in, I need to share our standard disclaimer: This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

    **JORDAN**: Absolutely. Now Alex, let's talk numbers because Stryker really brought the heat this quarter.

    **ALEX**: They sure did, Jordan. Stryker crushed it with 11% organic sales growth in Q4, hitting over $25 billion in sales for the full year. That's their fourth consecutive year of double-digit organic growth. And here's what I love - they managed 10.3% growth for the full year against a tough 10.2% comparable from 2024.

    **JORDAN**: The consistency is remarkable. And it wasn't just the top line - adjusted earnings per share jumped 11.5% to $4.47 in the quarter, with full-year EPS up 11.8% to $13.63. What really stands out to me is they achieved this while managing $400 million in tariff headwinds, including an incremental $200 million hit they're expecting in 2026.

    **ALEX**: That tariff management is impressive. Preston Wells, their CFO, mentioned they're absorbing these costs while still driving meaningful operating margin expansion. Speaking of which, they delivered their second consecutive year of at least 100 basis points of margin expansion. That shows real operational muscle.

    **JORDAN**: Let's break down the business segments because there were some real standouts. MedSurg and Neurotechnology posted 12.6% organic growth, with U.S. growth hitting 13%. The instruments business was particularly hot with 19.1% U.S. growth driven by strong capital demand.

    **ALEX**: And then there's the Mako story - which honestly feels like the star of this whole show. Jordan, they had another record quarter for Mako installations, both in the U.S. and worldwide. Their installed base now includes over 3,000 Mako systems globally.

    **JORDAN**: The Mako 4 transition has been what Lobo called "an absolute home run." Here's a stat that blew me away - over two-thirds of their knee procedures and over one-third of hip procedures in the U.S. are now performed on Mako. One surgeon even told Lobo that the new revision hip application was like a "cheat code" for difficult procedures.

    **ALEX**: That's incredible feedback. And they're not stopping there - they're expanding Mako into shoulder applications mid-year, plus they just started cases on their handheld robot called Mako RPS. This is designed for surgeons who want robotic assistance but aren't ready for the full Mako system complexity.

    **JORDAN**: The RPS launch is smart positioning. It sits between their manual instruments and full Mako systems, potentially opening up new customer segments, especially in ambulatory surgery centers. Speaking of ASCs, they mentioned hips and knees are now in the high teens percentage flowing through that channel.

    **ALEX**: Let's talk guidance because this is where Stryker shows confidence in their momentum. For 2026, they're guiding 8% to 9.5% organic sales growth and adjusted EPS of $14.90 to $15.10. That top end of the range is slightly higher than where they started 2025, which Lobo says reflects their elevated capital backlog and strong procedural outlook.

    **JORDAN**: And here's something interesting from the Q&A - when asked if 10% growth was still possible, Lobo said "certainly possible" for their fifth consecutive year of double-digit growth. The confidence seems genuine, backed by that strong order book and Mako momentum.

    **ALEX**: There were some organizational changes wo

    This episode includes AI-generated content.
    Show more Show less
    9 mins
No reviews yet